Metabolic disorders in patients with polyvascular disease according to the KAMMA register

Gregory Arutyunov; Ekaterina Tarlovskaya; Alexander Arutyunov; Roman Bashkinov; Ekaterina Evdokimova; Anastasiia Ermilova; Evgenii Melnikov; Tatiana Batluk; Marina Trubnikova; Elizaveta Gordeychuk; Dmitrii Evdokimov

doi:10.1530/endoabs.110.EP987

EP987

Prev Next

Section Contents Cite

Endocrine Abstracts (2025) 110 EP987 | DOI: 10.1530/endoabs.110.EP987

ECEESPE2025 ePoster Presentations Metabolism, Nutrition and Obesity (164 abstracts)

Metabolic disorders in patients with polyvascular disease according to the KAMMA register

Gregory Arutyunov ^1,2 , Ekaterina Tarlovskaya ^1,3 , Alexander Arutyunov ^1,4 , Roman Bashkinov ^1,5 , Ekaterina Evdokimova ^5,6 , Anastasiia Ermilova ¹ , Evgenii Melnikov ^1,5 , Tatiana Batluk ¹ , Marina Trubnikova ¹ , Elizaveta Gordeychuk ¹ & Dmitrii Evdokimov ^1,5

Author affiliations

¹Association "Eurasian Association of Internal Medicine", Moscow, Russian Federation; ²Pirogov Russian National Research Medical University, Moscow, Russian Federation; ³Privolzhsky Research Medical University, Nizhny Novgorod, Russian Federation; ⁴National Institute of Health after academician S. Avdalbekyan, Yerevan, Armenia; ⁵NWSMU named after I.I. Mechnikov, Saint-Petersburg, Russian Federation; ⁶Association "Eurasian Association of Internal Medicine", Saint-Petersburg, Russian Federation

JOINT971

Aim: To investigate the characteristics of metabolic status in individuals with polyvascular disease (PVD).

Materials and Methods: KAMMA (NCT05189847) is an international register of real clinical practice, comprising 28 centres across the Russian Federation, the Republic of Kazakhstan, the Republic of Uzbekistan and the Republic of Belarus. The register includes 3059 individuals over the age of 18 with confirmed atherosclerosis in two or more arterial basins, as well as one or more atherosclerosis risk factors. The ankle-brachial index (ABI) was measured for all the patients in the study, either manually or automatically. The level was considered to be low if it was ≤0.9, normal if it was between 0.9 and 1.4, and high if it was ≥1.4.

Results: The mean age of the people included in the study was 66 years [59-72], and 60.3% of them were men. The most common comorbidities were hypertension in 96%, coronary heart disease in 94.8%, history of myocardial infarction in 47%, heart failure in 81%, chronic kidney disease (CKD) ≥C3A stage in 24.2%, and chronic lower-extremity arterial insufficiency in 21%. In the whole population, the mean body mass index was 29.4 [26.0;32.5] kg/m², corresponding to overweight; waist circumference was 97 [88;105] cm, corresponding to abdominal obesity. 27% of patients had dyslipidemia with low-density lipoproteins (LDL) elevation >4.9 mmol/l, 3.4% of patients had familial hypercholesterolemia. In most cases, LDL target levels were not achieved despite treatment with statins (92.8%). Alternative hypolipidemic drugs (omega-3 polyunsaturated fatty acids 11.2%, ezetimibe 8.4%, fibrates 2.9%, antibodies to PCSK9 1.4%) were used less frequently. 10.2% of patients had prediabetes, while 32.2% had type 2 diabetes mellitus (DM), with a mean glycated hemoglobin level of 6.4 [5.7;7.2] %. Patients with type 2 DM had lowered ABI more often than patients without type 2 DM (47.6% vs 36.1%, P <0.001). In 7% of patients with type 2 DM, the course of the disease was complicated by the development of diabetic foot. Among them, lowered ABI (76.8% vs 38.9%, P <0.001), CKD C3 (14.5% vs 4.8%, P <0.001) and C4 (5.8% vs 0.6%, P <0.001) stages were significantly more common.

Conclusion: The complex of identified metabolic disorders, together with inadequate control of key risk factors (presence of overweight, abdominal obesity, dyslipidemia, type 2 DM, prediabetes), may contribute to the development and accelerated progression of PVD and potentially have a negative impact on its outcome.